Antares Pharma, Inc. (ATRS)

[Birdstone]

I for one would be thrilled to recoup the $4 level on a buyout. $520 million is still nothing to sneeze at when you're losing money or barely breaking even, and it's questionable if or when your products will begin to generate sufficient returns for shareholders.

We've talked about the pipeline for years and here we sit, 2nd quarter 2014 will show an $8 million loss or so, 3rd quarter will lose another $6 million. Perhaps the 4th quarter will see us close in on the breakeven level which would be a sight for sore eyes.

Think about the investors that scooped up those 12.5 million shares at $4 in late 2012, and how disappointed they must be.